T1	intervention 99 108	docetaxel
T2	control 116 178	paclitaxel plus pirarubicin hydrochloride and cyclophosphamide
T3	total-participants 392 394	97
T4	intervention-participants 464 466	49
T5	control-participants 519 521	48
T6	eligibility 342 379	locally advanced breast cancer (LABC)
T7	outcome 613 621	clinical
T8	outcome 626 663	pathological complete remission rates
T9	iv-bin-percent 687 692	28.6%
T10	iv-bin-percent 697 702	26.5%
T11	cv-bin-percent 780 785	10.4%
T12	cv-bin-percent 790 794	8.3%
T13	outcome 813 862	pathological negative rate of regional lymph node
T14	iv-bin-percent 943 948	40.6%
T15	cv-bin-percent 953 958	12.9%
T16	outcome 970 1010	grade III-IV blood system toxic reaction
T17	iv-bin-percent 1024 1029	71.4%
T18	outcome 1037 1066	grade II-IV liver dysfunction
T19	iv-bin-percent 1070 1075	53.1%
T20	outcome 1086 1091	edema
T21	iv-bin-percent 1095 1100	24.5%
T22	cv-bin-percent 1182 1187	46.9%
T23	cv-bin-percent 1189 1194	27.1%
T24	cv-bin-percent 1197 1201	4.2%
